Jupiter Asset Management’s PTC Therapeutics PTCT Stock Holding History

Jupiter Asset Management’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$57.7M	Sell	707,450 -4,007	-0.6%	-$289K	0.29%	98
2026 Q1	$48.5M	Buy	711,457 +350,298	+97%	+$24.8M	0.26%	113
2025 Q4	$27.4M	Buy	+361,159	New	+$26.2M	0.22%	127
2025 Q3	–	Sell	-46,104	Closed	-$2.25M	–	522
2025 Q2	$2.25M	Buy	+46,104	New	+$2.19M	0.02%	330

Other funds holding PTCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Asset Management's PTCT Position: Q2 2026 in Review

Jupiter Asset Management reduced its PTC Therapeutics (PTCT) stake by 0.56% in Q2 2026, selling an estimated $289K and leaving 707,450 shares worth $57.7M. The position accounts for 0.29% of the portfolio, ranked #98.

Jupiter Asset Management first reported a position in PTCT in Q2 2025 and has held it in 4 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

Jupiter Asset Management held 707,450 shares of PTC Therapeutics worth $57.7M as of Q2 2026.
Jupiter Asset Management sold 4,007 PTC Therapeutics shares in Q2 2026, an estimated $289K.
PTC Therapeutics made up 0.29% of Jupiter Asset Management's portfolio in Q2 2026, its #98 holding.
Jupiter Asset Management first reported a position in PTC Therapeutics in Q2 2025 and has held it in 4 quarters since.
382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Jupiter Asset Management's 13F filing for Q2 2026, filed 10 Aug 2026.